[MO6] Mini-Oral Session 6　Hepatobiliary / Pancreatic Cancer 3（Pancreatic Cancer 2）
【E】

[MO6-3] Clinical and biological results of tocilizumab + rechallenge-gemcitabine/nab-paclitaxel for metastatic pancreatic cancer

^○Shuichi Mitsunaga^1,2, Ikeda Masafumi¹, Aoki Kazunori³, Imaoka Hiroshi¹, Sasaki Mitsuhito¹, Watanabe Kazuo¹, Ochiai Atsushi², Yamaguchi Kyoko⁴, Sawada Noriaki⁵, Fujii Etsuko⁶, Nishidate Masanobu⁴, Fujitomo Takashi⁶, Mizuno Hideaki⁶, Kayukawa Yoko⁵, Makikawa Mayu⁴, Tsunoda Hiroyuki⁶, Terao Kimio⁴ (1.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 2.Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 3.Division of Molecular and Cellular Medicine, National Cancer Center, 4.Pharmaceutical Science Dept, Chugai Pharmaceutical Co., Ltd, 5.Discovery Pharmacology Dept, Chugai Pharmaceutical Co., Ltd, 6.Discovery Technology Dept, Chugai Pharmaceutical Co., Ltd)